Ophthalmic instrument distributor Medix21 has introduced two new AmnioTek products to New Zealand and is poised to introduce a third.
The three new processed human amniotic membrane (AM) products represent the latest regenerative biologics technology for treating the ocular surface, said Camille Furnandiz, Medix 21 Surgical New Zealand sales manager.
- AmnioTek 2 is twice as thick (100μm vs 50μm) as the standard AmnioTek product, making the graft much easier to suture, explained Jay Tardugno, managing director of ISP Surgical, which specialises in distributing regenerative AM grafts. “The handling is much better as it is thicker. It is also more resilient and will stay around the wound area much longer to promote re-epithelialization of the surrounding conjunctiva. The perfect thickness for a scaffolding graft-tissue substitute.”
- AmnioTek-G is semi-transparent and three times as thick (150μm) and was developed specifically to cover different types of glaucoma drainage devices. It reduces surgical times because it does not require rehydration and is easy to handle compared with alternative products, said Tardugno.
- AmnioTek-C Vision incorporates a hole for the pupil, so vision is not affected while the graft is on the eye, he said. “Our New AmnioTek-C Vision product is also 100μm so it can treat a wide variety of corneal wounds, specifically the stubborn, non-healing PEDs (persistent corneal epithelial defects) and deep neurotrophic ulcers.”
